scholarly journals Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

2012 ◽  
Vol 27 (8) ◽  
pp. 1627-1634 ◽  
Author(s):  
Richard M Jacques ◽  
Steven Boonen ◽  
Felicia Cosman ◽  
Ian R Reid ◽  
Douglas C Bauer ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Fracture Risk ◽  
Postmenopausal Osteoporosis ◽  
Bone Mineral ◽  
Nonvertebral Fracture ◽  
Mineral Density ◽  
Total Hip ◽  
Relationship Of

Abstract #880: Greater Increases in Bone Mineral Density Do Not Relate to Greater Decreases in Nonvertebral Fracture Risk

2005 ◽  
Vol 11 ◽  
pp. 47
Author(s):  
Nelson B. Watts ◽  
Piet Geusens ◽  
Ian P. Barton ◽  
Dieter Felsenberg
Keyword(s):  
Bone Mineral Density ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Nonvertebral Fracture ◽  
Mineral Density

scholarly journals Relationship Between Bone Mineral Density T ‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment

2019 ◽  
Vol 34 (6) ◽  
pp. 1033-1040 ◽  
Author(s):  
S Ferrari ◽  
C Libanati ◽  
Celia Jow Fang Lin ◽  
JP Brown ◽  
F Cosman ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Nonvertebral Fracture ◽  
Mineral Density ◽  
T Score ◽  
Denosumab Treatment

Annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized placebo-controlled trial

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4515-4515 ◽  
Author(s):  
M. D. Michaelson ◽  
H. Lee ◽  
D. S. Kaufman ◽  
P. W. Kantoff ◽  
J. Finkelstein ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Bone Mineral ◽  
Gnrh Agonist ◽  
Gonadotropin Releasing Hormone ◽  
Mineral Density ◽  
Total Hip

4515 Background: Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density (BMD) and increase fracture risk in men with prostate cancer. Zoledronic acid (4 mg IV every 3 months) increases BMD in GnRH agonist treated men. Intermittent zoledronic acid (4 mg IV once annually) increases BMD in postmenopausal women with osteoporosis but the efficacy of the annual treatment schedule in hypogonadal men is unknown. Methods: In a 12-month open-label study, men with nonmetastatic prostate cancer (n = 44) who were receiving a GnRH agonist were assigned randomly to zoledronic acid (4 mg IV × 1) or placebo. BMD of the posteroanterior lumbar spine and total hip were measured by dual energy x-ray absorptiometry at baseline and month 12. Serum N-telopeptide, a marker of osteoclast activity, was measured every 3 months. Results: Mean (± SE) BMD of the posteroanterior lumbar spine increased by 4.0 ± 0.9 in men treated with zoledronic acid and decreased by 3.1 ± 0.9 percent in men who received placebo (P < 0.001 for between-group comparison). BMD of the total hip decreased by 0.7 ± 0.6 percent in men treated with zoledronic acid and decreased by 1.9 ± 0.7 percent in men who received placebo (P = 0.005). Compared to placebo, zoledronic acid significantly decreased serum N-telopeptide throughout the 12-month study (P < 0.05). Conclusions: In men receiving a GnRH agonist for prostate cancer, a single treatment of zoledronic acid significantly increased bone mineral density of the total hip and spine at 12 months. Annual zoledronic acid may provide a convenient and effective strategy to prevent bone loss in hypogonadal men. This study was supported in part by Novartis Oncology and by the Prostate Cancer Foundation. [Table: see text]

scholarly journals Bone Mineral Density and Fracture Risk Assessment to Optimize Prosthesis Selection in Total Hip Replacement

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Þröstur Pétursson ◽  
Kyle Joseph Edmunds ◽  
Magnús Kjartan Gíslason ◽  
Benedikt Magnússon ◽  
Gígja Magnúsdóttir ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Fracture Risk ◽  
Total Hip Replacement ◽  
Bone Mineral ◽  
Hip Replacement ◽  
Risk Index ◽  
Patient Specific ◽  
Mineral Density ◽  
Total Hip ◽  
And Gender

The variability in patient outcome and propensity for surgical complications in total hip replacement (THR) necessitates the development of a comprehensive, quantitative methodology for prescribing the optimal type of prosthetic stem: cemented or cementless. The objective of the research presented herein was to describe a novel approach to this problem as a first step towards creating a patient-specific, presurgical application for determining the optimal prosthesis procedure. Finite element analysis (FEA) and bone mineral density (BMD) calculations were performed with ten voluntary primary THR patients to estimate the status of their operative femurs before surgery. A compilation model of the press-fitting procedure was generated to define a fracture risk index (FRI) from incurred forces on the periprosthetic femoral head. Comparing these values to patient age, sex, and gender elicited a high degree of variability between patients grouped by implant procedure, reinforcing the notion that age and gender alone are poor indicators for prescribing prosthesis type. Additionally, correlating FRI and BMD measurements indicated that at least two of the ten patients may have received nonideal implants. This investigation highlights the utility of our model as a foundation for presurgical software applications to assist orthopedic surgeons with selecting THR prostheses.

scholarly journals Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density

2009 ◽  
Vol 94 (9) ◽  
pp. 3215-3225 ◽  
Author(s):  
Richard Eastell ◽  
Dennis M. Black ◽  
Steven Boonen ◽  
Silvano Adami ◽  
Dieter Felsenberg ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Femoral Neck ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Mineral Density

scholarly journals Association between polymorphisms in GGPS1 and RANKL genes and postmenopausal osteoporosis in Romanian women

2019 ◽  
Vol 10 (Vol.10, No.3) ◽  
pp. 252-258
Author(s):  
Alina Deniza CIUBEAN ◽  
Laszlo IRSAY ◽  
Rodica Ana UNGUR ◽  
Viorela Mihaela CIORTEA ◽  
Ileana Monica BORDA ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Fracture Risk ◽  
Postmenopausal Osteoporosis ◽  
Bone Mineral ◽  
Strong Association ◽  
Fragility Fractures ◽  
Mineral Density ◽  
Density Values ◽  
Study Participants ◽  
The Relationship

Objectives: This study aimed to assess the relationship between bone mineral density, fragility fractures, fracture risk and polymorphisms of two osteoporosis-candidate genes (GGPS1 and RANKL) in Romanian women with postmenopausal osteoporosis. Methods: An analytical, prospective, transversal, observational, case-control study on 364 postmenopausal women, of which 228 were previously diagnosed with osteoporosis, was carried out between June 2016 and August 2017 in Cluj Napoca, Romania. Clinical data and blood samples were collected from all study participants. Polymorphisms in GGPS1 and RANKL genes were genotyped using TaqMan SNP Genotyping assays, run on a QuantStudio 3 real-time PCR machine. Results: The CT genotype in GGPS1 rs10925503 was associated with significant lower bone mineral density values at lumbar spine and femoral neck sites and a higher fracture risk compared to controls. No significant association was found between genotypes of RANKL rs2277439 with bone mineral density or fracture risk compared to the healthy controls. Conclusions: Our study showed a strong association between low bone mineral density and genotype CT of GGPS1 rs10925503 polymorphisms. No association was found for RANKL rs2277439 polymorphism.

Sign in / Sign up

Export Citation Format

Share Document